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JAK2V617F, an activation mutant form of tyrosine kinase JAK2, is
found in the majority of patients with myeloproliferative
neoplasms (MPNs) including polycythemia vera (PV), essential
thrombocythemia (ET) and primary myeloﬁbrosis. Overwhelming
studies have demonstrated the pathogenicity of JAK2V617F.
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However, some still doubt that JAK2V617F is a primary molecular
defect in causing the malignant disease. This uncertainty partly
comes from the ﬁnding of biallelic JAK2V617F mutations.
2- -4 By
using allele-speciﬁc PCR ampliﬁcation of genomic DNAs and
subcloning, Olcaydu et al.
2 demonstrated an infrequent occur-
rence of biallelic JAK2V617F mutations in o5% of MPN patients.
However, a subsequent study by Lambert et al.
3 employed cDNA
and identiﬁed biallelic JAK2V617F mutations in the majority of
patients with ET. Based on this ﬁnding, it was concluded that
independent JAK2V617F mutation events may occur in ET patients
on a polyclonal background, and therefore, the presence of a JAK2
mutation in ET patients should not be equated with a malignant
disease. A recent study by Beer et al.
4 essentially conﬁrmed the
results using each individual method but cautioned that
PCR artifacts may affect the outcome, and they concluded that
the true prevalence of biallelic JAK2 mutations in ET is
approximately 5--10%.
Although the previous studies were performed with patient
DNA samples of unknown compositions, we believe it is important
to clarify them by using DNAs with absolute allelic sequence
information. For this purpose, we ampliﬁed a 3707-bp DNA
fragment from blood genomic DNAs of a heterozygous
JAK2V617F-positive PV patient with primers P1 50-CAGGCTGGAAT
GCAGAAATACTAT-30 and P2 50-ATCTAAGAAGCACAATAAAGCAAG
GT-30 by using the high-ﬁdelity Phusion polymerase. The fragment
spans intron 12--14 of the JAK2 gene and contains single-
nucleotide polymorphism (SNP) rs10974944, the V617F mutation
site, and SNP rs12343867. Upon cloning into the pBluescript KS
vector, two clones, representing two distinct JAK2 alleles, were
veriﬁed by complete DNA sequencing and were designated
C--G--T for wild-type JAK2 with two non-risk SNPs and G--T--C for
mutant JAK2V617F DNA with two risk SNPs as illustrated in
Figure 1a. The DNAs were puriﬁed and mixed in equal proportions
for further PCR ampliﬁcation. PCR was conducted with primers
derived from the T3 and T7 promoter regions of the vector, giving
rise to a 3883-bp product. We ﬁrst ran the PCR under the standard
conditions recommended by the manufacturer of the Phusion
polymerase, except that the extension time was 3.5min instead of
the suggested 15s/kb. A typical reaction with a total volume of
20ml contained 10ng mixed DNA templates, 0.4U of Phusion
DNA polymerase, 0.2mM dNTP (each) and 0.2mM primers (each).
The PCR was run for 25 or 40 cycles. Reactions were also
conducted with three times the amount of Phusion polymerase of
the standard procedure and a longer extension time of 7min. The
PCR products were digested with EcoRI and XhoI, and then ligated
into the pBluescript KS vector opened with the same enzymes.
The ligation products were used to transform Escherichia coli cells.
At least 50 plasmid DNA clones were sequenced for each set of
PCR conditions. The percentages of different clones are summar-
ized in Figure 1b. In control experiments without PCR ampliﬁca-
tion, the sequencing results revealed approximately equal
portions of C--G--T and G--T--C DNA clones without any chimeric
products, indicating that the restriction enzyme digestion, DNA
ligation and E. coli cell transformation process are highly reliable.
However, after PCR ampliﬁcation under the standard conditions
for 40 cycles, eight different DNA clones were found, six of which
were new chimeric products, representing all possible chimeric
recombinations. The frequency of each chimeric product appar-
ently correlated with the relative position of each site with C--T--C/
G- -G- -T4C -- G -- C/G -- T -- T4C--T--T/G--G--C. Interestingly, using
more Phusion polymerase, increasing the extension time and
shortening PCR cycles signiﬁcantly reduced the percentage of
chimeric products, although they could not be completely
eliminated. It should be noted that generation of the chimeric
products is likely caused by template-switching during PCR rather
than by new point mutations. Out of 500 clones sequenced, not a
single point mutation was found, conﬁrming the high ﬁdelity of
the Phusion polymerase.
To review the method employed in the study by Lambert et al.,
3
we also conducted experiments with cDNA. For this purpose, total
RNAs were isolated from recombinant E. coli cells carrying the
C--G--T and G--T--C plasmid DNAs by using a hot phenol
extraction/ethanol precipitation protocol. This was followed by
treatment with DNase I to remove contaminated DNAs. The RNAs
were then mixed in equal proportions for synthesis of single-
strand cDNAs by reverse transcription with either random primers
or speciﬁc primer P2. PCR was conducted for 25 cycles with primer
P1 and P2 under the conditions described above with 3 
Phusion enzyme and 7min extension time. PCR products were
cloned into the pBluescript KS vector opened with EcoRV. E. coli
colonies were picked based on blue/white selection, and over 50
plasmid DNAs were sequenced. The data are presented in
Figure 1b (two far right columns). When random primers were
used for reverse transcription, nearly 50% of the clones contained
chimeric DNA products. With speciﬁc primers, the percentage was
reduced to o30%. We believe that random primers more likely
produce various cDNA fragments, which are combined using
PCR to generate chimeric DNA products. Our data suggest that the
PCR ampliﬁcation of reversely transcribed cDNA is a very
unreliable way to deﬁne allele speciﬁcity, especially if random
primers were used for cDNA synthesis.
By using puriﬁed plasmid DNAs, our study demonstrated that
PCR could generate chimeric products when mixed DNA
templates were used. This is likely caused by template-switching
resulting from incomplete extension of the DNA strand as
illustrated in Figure 1c. In principle, an incompletely extended
PCR product will serve as a primer and may anneal to a different
strand in the subsequent PCR cycle, thereby producing a chimeric
DNA product. This is particularly likely to occur when two SNP or
mutation sites are distant from each other, which requires extra
extension time to synthesize fully extended products, when DNA
polymerase activity is reduced due to inhibition by impurities in
DNA samples or exhaustion after many PCR cycles and when
fragmented DNAs are present in the templates, such as in the case
of reversely transcribed cDNA and shared genomic DNAs. Our
study demonstrated that the production of chimeric PCR products
in reactions with mixed templates appears to be inevitable. We
can adjust PCR conditions to reduce the possibility but can never
completely prevent this from occurring. Therefore, our study
demonstrates that the PCR ampliﬁcation can give rise to the
artifactual appearance of biallelic JAK2V617F mutations. Of course,
our data does not necessarily disprove previous conclusions about
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investigators. After all, in at least one ET patient, the conclusion is
also supported by the presence of JAK2V617F-positive erythroid
colonies with different X-allele inactivations.
3 Whether or not
biallelic JAK2V617F mutations occur certainly warrants further
investigation using more reliable methodologies.
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Figure 1. PCR artifacts cause production of chimeric DNA molecules
in reactions with mixed templates. (a) Generation of DNA clones
with allele-speciﬁc wild-type or mutant forms of JAK2. A 3707-bp
DNA fragment was obtained by PCR ampliﬁcation of genomic DNAs
of a JAK2V617F-positive PV patient and cloned into the pBluescript
KS vector. The plasmid DNAs were veriﬁed by DNA sequencing and
were designated C--G--T for wild-type JAK2 with two non-risk SNPs
(Rs10974944 and Rs12343867) and G--T--C for mutant JAK2V617F
DNA with two risk SNPs as indicated. (b) Production of chimeric
DNA molecules by PCR ampliﬁcation of mixed templates. Puriﬁed
C--G--T and G--T--C plasmid DNAs mixed in equal proportions were
non-ampliﬁed or ampliﬁed with PCR under the indicated conditions
and then digested with EcoRI and XhoI restriction enzymes. The DNA
fragments were ligated into the pBluescript KS vector opened
with EcoRI and XhoI. Alternately, total RNAs were isolated from
recombinant E. coli cells carrying the C--G--T or G--T--C plasmid
DNA, treated with DNase I, mixed in equal proportions and reversely
transcribed by using either random primers or speciﬁc primer P2.
The single-stranded cDNAs were ampliﬁed using PCR under the
indicated conditions and the PCR products were ligated into
the pBluescript KS vector opened with EcoRV restriction enzyme.
The DNA ligation products were used to transform E. coli cells, and
plasmid DNAs from transformed E. coli colonies were sequenced
to verify their identities. Data represent percentages of colonies
carrying different plasmid DNAs. Anything other than C--G--T and
G--T--C represents a chimeric product produced by PCR. A minimum
of 50 clones were sequenced for each set of PCR conditions.
(c) Template-switch caused by incomplete PCR extension is a
possible mechanism to explain the generation of chimeric DNA
molecules.
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